FDA
-
-
-
-
-
-
-
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
-
-
-
-
-
-
-
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
-
-
-
-
-
-
-
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
-
-
-
-
-
-
-
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
-
-
-
-
-
-
-
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
-
-
-
-
-
-
-
Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations
-
-
-
-
-
-
-
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
-
325,451 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

